Boston, MA – According to filings with the U.S. Securities and Exchange Commission, DermBiont is raising $39,520,131.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Karl Beutner played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About DermBiont
DermBionts mission is to become the worlds leading precision dermatology company developing targeted topical therapeutics that treat, cure, and prevent diseases. The company aims to impact the root cause of skin diseases with biotherapeutics that repair an imbalance of the microbiome as well as through the development of targeted small molecule therapeutics with well-defined mechanisms of action. DermBionts biotherapeutics discovery team leverages computational biology and a proprietary bioinformatics platform to identify clinically meaningful dysbiosis related to common skin diseases and mines a curated library of microbes to build a pipeline of products to treat identified dysbiosis across indications.

To learn more about DermBiont, visit http://www.dermbiont.com/

Contact:
Karl Beutner, Chief Executive Officer
510-607-8155
https://www.linkedin.com/in/karl-beutner-m-d-ph-d-785b0019/

SOURCE: http://www.intelligence360.io
Copyright (c) 2021 SI360 Inc. All rights reserved